Cantor Fitzgerald’s Inhibrx INBX Stock Holding History

Cantor Fitzgerald’s Portfolio INBX Stock Details INBX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q3	–	Sell	-18,263	Closed	-$259K	–	254
2024 Q2	$259K	Buy	+18,263	New	+$285K	0.05%	137

Other funds holding INBX

Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Walleye Capital New York $24B AUM 37.67% 1-Year Est. Return

Sofinnova Investments Menlo Park, California $2.63B AUM 117.41% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Slotnik Capital Dallas, Texas $342M AUM 105.92% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Cantor Fitzgerald's INBX Position: Q3 2024 in Review

Cantor Fitzgerald sold out of Inhibrx (INBX) in Q3 2024, closing a stake of 18,263 shares — an estimated $259K sold.

Cantor Fitzgerald first reported a position in INBX in Q2 2024 and held it in 1 quarter. The position peaked at $259K in Q2 2024. 96 funds tracked by Wall St. Rank hold INBX as of Q3 2024.

Cantor Fitzgerald reported no remaining Inhibrx position as of Q3 2024 after selling out during the quarter.
Cantor Fitzgerald sold 18,263 Inhibrx shares in Q3 2024, an estimated $259K.
Cantor Fitzgerald first reported a position in Inhibrx in Q2 2024 and held it in 1 quarter.
Cantor Fitzgerald's Inhibrx position peaked at $259K in Q2 2024.
96 funds tracked by Wall St. Rank held Inhibrx as of Q3 2024.

Based on Cantor Fitzgerald's 13F filing for Q3 2024, filed 14 Nov 2024.